Skip navigation
Por favor, use este identificador para citar o enlazar este ítem: http://repositorio2.unb.br/jspui/handle/10482/29786
Ficheros en este ítem:
Fichero Tamaño Formato  
ARTIGO_FieldValidationLeishmania.pdf734,86 kBAdobe PDFVisualizar/Abrir
Título : Field validation of a Leishmania (Leishmania) mexicana exo-antigens ELISA for diagnosing tegumentary leishmaniasis in regions of Leishmania (Viannia) predominance
Autor : Soares, Killarney Ataide
Urdapilleta, Ada Amália Ayala
Santos, Gilcilene Maria dos
Carneiro, Andréa Lisboa
Gomes, Ciro Martins
Roselino, Ana Maria
Sampaio, Raimunda Nonata Ribeiro
Assunto:: Diagnóstico
Controle de doenças
Doenças infecciosas
Leishmaniose
Fecha de publicación : may-2015
Editorial : Brazilian Society of Infectious Diseases
Citación : SOARES, Killarney Ataide et al. Field validation of a Leishmania (Leishmania) mexicana exo-antigens ELISA for diagnosing tegumentary leishmaniasis in regions of Leishmania (Viannia) predominance. Brazilian Journal of Infectious Diseases, Salvador, v. 19, n. 3, p. 302-307, maio/jun. 2015. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702015000300302&lng=en&nrm=iso>. Acesso em: 5 abr. 2018. doi: http://dx.doi.org/10.1016/j.bjid.2015.03.010.
Abstract: Background: several tests are performed to obtain better accuracy when diagnosing American tegumentary leishmaniasis (ATL). It is believed that antigens released via secretion, excretion and metabolism are more specific than are antigens released by the lysis of Leishmaniaparasites. Such antigens are known as exo-antigens (exo-Ag) and are formed from products released by cultured parasites in a way that is similar to that in which they cause infections in hosts. Objective: we attempted to validate a Leishmania mexicanaELISA exo-Ag for ATL diagnosis in Midwestern Brazil. Methods: a total of 281 patients were included in the study. We analysed pre-treatment blood from 98 ATL patients; out of those, 85.7% and 14.3% had cutaneous and mucosal forms, respectively. Results: the exo-Ag accuracy was 83.99% (95% CI = 79.24-87.81) with a sensitivity value of 90.82% (95% CI = 83.46-95.09) and an overall specificity value of 80.33% (95% CI = 73.97-85.44). The positive predictive value and negative predictive value were 71.20% (95% CI = 62.72-78.41) and 94.23% (95% CI = 89.40-96.94), respectively. Among healthy controls, exo-Ag had a specificity of 91.25% (95% CI = 83.02-95.70); additionally, the test had specificity rates of 66.67% (95% CI = 46.71-82.03) in Chagas disease patients, 60.61% (95% CI = 43.68-75.32) in patients with rheumatic diseases, 76.92% (95% CI = 49.74-91.82) in pemphigus foliaceus patients, 87.50% (95% CI = 52.91-97.76) in leprosy patients, 87.50% (95% CI = 63.98-96.50) in VRDL-positive patients, and 77.78 (95% CI = 45.26-93.68) in deep mycosis patients. Conclusion: based on the indicators of validity, we conclude that the results obtained in this study enable the recommendation of the exo-Ag ELISA for ATL diagnosis once it presented a reasonable accuracy compared to classical methods. Cost evaluations are necessary to completely define the role of this technique in large scale.
metadata.dc.description.unidade: Faculdade de Medicina (FMD)
Licença:: Brazilian Journal of Infectious Diseases - This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY NC ND 4.0). Fonte: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702015000300302&lng=en&nrm=iso. Acesso em: 5 abr. 2018.
DOI: http://dx.doi.org/10.1016/j.bjid.2015.03.010
Aparece en las colecciones: Artigos publicados em periódicos e afins

Mostrar el registro Dublin Core completo del ítem " class="statisticsLink btn btn-primary" href="/jspui/handle/10482/29786/statistics">



Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.